[go: up one dir, main page]

FI960803L - Inhibitors of TNF-alpha secretion - Google Patents

Inhibitors of TNF-alpha secretion Download PDF

Info

Publication number
FI960803L
FI960803L FI960803A FI960803A FI960803L FI 960803 L FI960803 L FI 960803L FI 960803 A FI960803 A FI 960803A FI 960803 A FI960803 A FI 960803A FI 960803 L FI960803 L FI 960803L
Authority
FI
Finland
Prior art keywords
tnf
inhibitors
alpha secretion
secretion
alpha
Prior art date
Application number
FI960803A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI960803A7 (en
FI960803A0 (en
Inventor
Roy A Black
Jeffrey N Fitzner
Paul R Sleath
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI960803A0 publication Critical patent/FI960803A0/en
Publication of FI960803L publication Critical patent/FI960803L/en
Publication of FI960803A7 publication Critical patent/FI960803A7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI960803A 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion FI960803A7 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US18301994A 1994-01-18 1994-01-18
PCT/US1994/009343 WO1995006031A1 (en) 1993-08-23 1994-08-19 Inhibitors of tnf-alpha secretion

Publications (3)

Publication Number Publication Date
FI960803A0 FI960803A0 (en) 1996-02-22
FI960803L true FI960803L (en) 1996-04-22
FI960803A7 FI960803A7 (en) 1996-04-22

Family

ID=26808203

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960803A FI960803A7 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion

Country Status (8)

Country Link
EP (1) EP0715619A4 (en)
JP (1) JPH09503201A (en)
AU (2) AU687436B2 (en)
CA (1) CA2170158A1 (en)
FI (1) FI960803A7 (en)
NO (1) NO960723L (en)
NZ (1) NZ271893A (en)
WO (1) WO1995006031A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI971412A0 (en) 1994-10-05 1997-04-04 Chiroscience Ltd Peptidyl compounds and their therapeutic use as inhibitors of metalloprotease
JPH11505532A (en) * 1995-05-10 1999-05-21 カイロサイエンス・リミテッド Peptide compounds inhibiting the release of metalloproteases and TNF and their therapeutic use
JPH11504646A (en) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド Peptide compounds inhibiting the release of metalloproteases and TNF and their therapeutic use
WO1996035712A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
WO1997009420A2 (en) * 1995-09-05 1997-03-13 Celltech Therapeutics Limited Dna sequences coding for a human metalloproteinase and variants thereof
CN1145637C (en) * 1995-10-05 2004-04-14 达尔文发现有限公司 Sulfur-substituted peptides as metalloprotease and TNF release inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
DE69615058T2 (en) 1995-11-23 2002-06-27 British Biotech Pharmaceuticals Ltd., Cowley METALLOPROTEINASE INHIBITORS
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
ATE220660T1 (en) 1996-09-10 2002-08-15 British Biotech Pharm CYTOSTATIC HYDROXAMIC ACID DERIVATIVES
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
CA2295440A1 (en) * 1997-06-18 1998-12-23 The Rockefeller University Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
WO1999018942A1 (en) * 1997-10-10 1999-04-22 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
GB9810464D0 (en) 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
JP2002525302A (en) * 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー Method of treating hair loss using ketoamides
CN1320028A (en) * 1998-09-30 2001-10-31 宝洁公司 Method of treating hair loss using sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
CN1342078A (en) * 1999-01-13 2002-03-27 朱马制药有限公司 Use of 3-isoxazolidinones and hydroxylamine acids for treatment of infections
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
AU2002230385A1 (en) * 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
JP2022512584A (en) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル EGFR inhibitor for treating keratoderma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870700065A (en) * 1984-12-19 1987-02-28 아놀드 자일러, 에른스트 알테르 Novel Carbonic Acid Ester
FR2609289B1 (en) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives

Also Published As

Publication number Publication date
EP0715619A4 (en) 1997-03-19
FI960803A7 (en) 1996-04-22
AU7569494A (en) 1995-03-21
WO1995006031A1 (en) 1995-03-02
AU687436B2 (en) 1998-02-26
NZ271893A (en) 1997-11-24
NO960723D0 (en) 1996-02-23
EP0715619A1 (en) 1996-06-12
JPH09503201A (en) 1997-03-31
AU5030298A (en) 1998-03-05
NO960723L (en) 1996-02-23
CA2170158A1 (en) 1995-03-02
FI960803A0 (en) 1996-02-22

Similar Documents

Publication Publication Date Title
FI960803L (en) Inhibitors of TNF-alpha secretion
FI933277A7 (en) Aminediol protease inhibitors
PL314838A1 (en) Inhibitors of bp-iv-serine protease
FI935020A7 (en) Interleukin-1b protease and interleukin-1b protease inhibitors
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
HU9500685D0 (en) Sulfonamide inhibitors of hiv-aspartyl protease
FI961886A7 (en) Human Kunitz-type protease inhibitors
FI962249A7 (en) Substituted pyrazolylbenzenesulfonamides for the treatment of inflammation
NO942064D0 (en) inhibitors
DK42093D0 (en) METHOD OF ADMINISTRATION
FI961976A7 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
AP9701054A0 (en) Inhibitors of cycteine protease
FI943234A0 (en) Human Kunitzt type protease inhibitor variant
FI943233A7 (en) Human Kunitz-type protease inhibitor variant
FI925787A7 (en) Saccharin derivative inhibitors of proteolytic enzymes
FI963655A7 (en) Enhanced secretion of polypeptides
DK0505222T3 (en) Method of freezing
FI943232A7 (en) Human Kunitz-type protease inhibitor variant
FI942625L (en) Peptide phosphinyloxymethyl ketones as inhibitors of interleukin-1beta-converting enzyme
PT927183E (en) SPIROCYLIC INHIBITORS OF METALOPROTEASES
FI943231L (en) Variants of the human Kunitz-type protease inhibitor
PL328665A1 (en) Inhibitors of serinic protease
AU2251892A (en) Inhibitors of picornavirus proteases
NO985214D0 (en) Inhibitors for production of s-CD23 and secretion of TNF
DK0623614T3 (en) 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as inhibitors of 5-lipoxygenase